"Methicillin-Resistant
Staphylococcus aureus (MRSA) - Japan Drug Forecast and Market
Analysis to 2024"is
the latest addition to MRR.Biz industry research reports collection.
With
the discovery of penicillin, the first naturally-occurring
antibiotic, in 1928, and its mass production in the early 1940s,
infections with Staphylococcus aureus were mostly treatable, without
any major complications. However, clinicians soon observed the
emergence of penicillin-resistant strains of S. aureus, which was
largely driven by bacterial expression of beta-lactamases.
Methicillin, a novel penicillin analogue that was resistant to
beta-lactamases, was introduced in 1959, and was initially effective
against penicillin-resistant S. aureus strains. However, this success
was short-lived, as the first methicillin-resistant S. aureus (MRSA)
strain had been identified in the lab by 1961, and cases of MRSA were
first observed in the clinic in 1968. Initially, MRSA strains only
occurred in small and local outbreaks across the US and Europe, but
they can now be found around the world.
For
the purposes of this report, GlobalData defines the Japanese MRSA
market as encompassing the sales of antimicrobial agents prescribed
for the treatment of hospitalized MRSA skin infections, pneumonia,
and bacteremia. Importantly, revenues generated by these products
outside of the aforementioned patient populations and clinical
scenarios are beyond the scope of this analysis.
View Report At :
http://www.marketresearchreports.biz/analysis/747734
Scope
- Overview of MRSA including
epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on the
key drugs in Japan including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in Japan from 2014-2024.
- Analysis of the impact of key
events as well the drivers and restraints affecting Japan MRSA
market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for MRSA.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2014-2024 in Japan.
Download Sample copy of this
Report at :
http://www.marketresearchreports.biz/sample/sample/747734
Table
of Contents
1.1
List of Tables
1.2
List of Figures
2
Introduction
2.1
Catalyst
2.2
Related Reports
2.3
Upcoming Related Reports
3
Disease Overview
3.1
Etiology
3.1.1
MRSA Strains
3.1.2
VISA Strains
3.1.3
VRSA Strains
3.2
Pathophysiology
3.2.1
Infection Sites
3.2.2
Expression of Virulence Factors
3.2.3
Mechanisms of Antibiotic Resistance
3.2.4
Biofilm Formation
3.3
Symptoms
3.4
Prognosis
3.4.1
Skin and Soft Tissue Infections
3.4.2
Pneumonia
3.4.3
Bacteremia
3.4.4
Chronic MRSA Infection
4
Disease Management
4.1
Diagnosis and Treatment Overview
4.1.1
Diagnosis
4.1.2
Treatment Guidelines
4.1.3
Clinical Practice
4.2
Japan
5
Competitive Assessment
5.1
Overview
5.2
Product Profiles - Glycopeptides and Lipoglycopeptides
5.2.1
Vancomycin
5.2.2
Dalvance (dalbavancin)
5.2.3
Orbactiv (oritavancin)
5.2.4
Vibativ (telavancin)
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment